Next-Generation Therapies

Discovery Articles

FDA Clears SAINT Rapid-Acting Brain Stimulation Approach for Those Suffering From Resistant Major Depression

READ

Posted: Thursday, September 15, 2022

FDA Clears SAINT Rapid-Acting Brain Stimulation Approach for Those Suffering From Resistant Major Depression

The last decade has seen a vast increase in the use of brain stimulation technologies to reduce symptoms of psychiatric illness. By far the most influential has been TMS, a non-invasive method employing magnets that generate electric fields which are thought to therapeutically alter the activity of neurons and brain circuits involved in depression and other disorders. TMS was pioneered by BBRF Scientific Council member Mark S. George, M.D., who used two early-career BBRF grants to develop the protocol ul

READ

Posted: Thursday, August 25, 2022

Team Assesses Safety of t-PBM, Non-Invasive Brain Stimulation Technology That Uses Light to Treat Depression and Anxiety

Comprehensive Analysis Suggests Metacognitive Training Can Be Effective in Schizophrenia and Psychotic Disorders

READ

Posted: Wednesday, July 20, 2022

Comprehensive Analysis Suggests Metacognitive Training Can Be Effective in Schizophrenia and Psychotic Disorders

1-Day Online CBT-Based Workshop Helped New Moms With Postpartum Depression

READ

Posted: Tuesday, July 12, 2022

1-Day Online CBT-Based Workshop Helped New Moms With Postpartum Depression

Some OCD Patients Who Attain “Wellness” After Exposure Therapy May Safely Taper Off Their SRI Medicines, Study Suggests

READ

Posted: Thursday, July 7, 2022

Some OCD Patients Who Attain “Wellness” After Exposure Therapy May Safely Taper Off Their SRI Medicines, Study Suggests

A Circuit Causally Linked With Spontaneous Nicotine Addiction Remissions May Be a Powerful Addiction Treatment Target

READ

Posted: Thursday, June 30, 2022

A Circuit Causally Linked With Spontaneous Nicotine Addiction Remissions May Be a Powerful Addiction Treatment Target

Researchers Discover Potentially Targetable Brain Circuit Controlling Cocaine Withdrawal Anxiety and Relapse

READ

Posted: Thursday, June 16, 2022

Researchers Discover Potentially Targetable Brain Circuit Controlling Cocaine Withdrawal Anxiety and Relapse

Combining Antidepressants Can Improve Outcomes in Patients with Severe Depression, Study Finds

READ

Posted: Thursday, June 9, 2022

Combining Antidepressants Can Improve Outcomes in Patients with Severe Depression, Study Finds

A Molecule Tested in Higher Primates Reduced Alcohol Consumption By Half

READ

Posted: Thursday, May 26, 2022

A Molecule Tested in Higher Primates Reduced Alcohol Consumption By Half

Stem Cell Technology Helps Identify a Potential Causal Mechanism in Schizophrenia That Could Be Targeted

READ

Posted: Thursday, May 5, 2022

Stem Cell Technology Helps Identify a Potential Causal Mechanism in Schizophrenia That Could Be Targeted

New Insights About Epilepsy Mechanism Suggest a Potential Treatment Target

READ

Posted: Thursday, April 28, 2022

New Insights About Epilepsy Mechanism Suggest a Potential Treatment Target

Team Tests Model to Enable More Effective Targeting of Non-Invasive TMS Treatments in Depression

READ

Posted: Thursday, April 21, 2022

Team Tests Model to Enable More Effective Targeting of Non-Invasive TMS Treatments in Depression

Imaging Analysis Suggests How Ketamine Treatment Might Have Helped Reduce Chronic PTSD Symptoms in Trial Subjects

READ

Posted: Thursday, April 14, 2022

Imaging Analysis Suggests How Ketamine Treatment Might Have Helped Reduce Chronic PTSD Symptoms in Trial Subjects

Team Uses Non-Invasive TMS Brain Stimulation to Activate Deep-Brain Region Important in Depression

READ

Posted: Thursday, April 7, 2022

Team Uses Non-Invasive TMS Brain Stimulation to Activate Deep-Brain Region Important in Depression

Adding Lithium Might Enable Ketamine's Antidepressant Activity in Ketamine-Resistant Patients, Study Suggests

READ

Posted: Thursday, March 3, 2022

Adding Lithium Might Enable Ketamine's Antidepressant Activity in Ketamine-Resistant Patients, Study Suggests

Discovering How tDCS Brain Stimulation Therapeutically Modifies Brain Circuits in Depression

READ

Posted: Thursday, February 17, 2022

Discovering How tDCS Brain Stimulation Therapeutically Modifies Brain Circuits in Depression

Evidence That Cognitive Behavioral Therapy Can Help People With Insomnia Who Also Are Depressed or Anxious

READ

Posted: Thursday, February 10, 2022

Evidence That Cognitive Behavioral Therapy Can Help People With Insomnia Who Also Are Depressed or Anxious

In Pilot Study, Oxygen Therapy for Moderate Depression Showed Beneficial Effects

READ

Posted: Thursday, January 6, 2022

In Pilot Study, Oxygen Therapy for Moderate Depression Showed Beneficial Effects

Two Signaling Pathways Involved in Regulating Synaptic Plasticity Suggest Novel Targets for Rapid-Acting Antidepressants

READ

Posted: Thursday, December 2, 2021

Two Signaling Pathways Involved in Regulating Synaptic Plasticity Suggest Novel Targets for Rapid-Acting Antidepressants

Non-Invasive Brain-Stimulation Protocol for Treatment-Resistant Depression Enabled 79% to Experience Remission Following 5-Day Treatment Course

READ

Posted: Thursday, November 11, 2021

Non-Invasive Brain-Stimulation Protocol for Treatment-Resistant Depression Enabled 79% to Experience Remission Following 5-Day Treatment Course

Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders

READ

Posted: Thursday, November 4, 2021

Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders

Positive Preliminary Results in Highly Personalized Deep-Brain Stimulation Therapy for Treatment-Resistant Depression

READ

Posted: Thursday, October 28, 2021

Positive Preliminary Results in Highly Personalized Deep-Brain Stimulation Therapy for Treatment-Resistant Depression

Mindfulness Training Plus tDCS Stimulation to Treat Cognitive Decline in Older Persons with Depression or Anxiety

READ

Posted: Thursday, October 21, 2021

Mindfulness Training Plus tDCS Stimulation to Treat Cognitive Decline in Older Persons with Depression or Anxiety

New Treatment Approach for Alcohol Use Disorder is Tested in Animals

READ

Posted: Thursday, October 14, 2021

New Treatment Approach for Alcohol Use Disorder is Tested in Animals

Study Indicates Brain Lesions and Treatment Targets in Depression Affect the Same Circuitry, Suggesting New Treatment Possibilities

READ

Posted: Thursday, August 5, 2021

Study Indicates Brain Lesions and Treatment Targets in Depression Affect the Same Circuitry, Suggesting New Treatment Possibilities

Positive Phase 3 Test of Rapid-Acting Oral Medicine for Postpartum Depression

READ

Posted: Wednesday, July 14, 2021

Positive Phase 3 Test of Rapid-Acting Oral Medicine for Postpartum Depression

Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment

READ

Posted: Thursday, July 1, 2021

Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment

Positive Results in Trial Testing ‘Laughing Gas’ in Severely Depressed Treatment-Resistant Patients

READ

Posted: Thursday, June 17, 2021

Positive Results in Trial Testing ‘Laughing Gas’ in Severely Depressed Treatment-Resistant Patients

Postpartum CBT for Depressed Moms May Help Lower Emotion-Regulation Risks in Infants

READ

Posted: Thursday, June 10, 2021

Postpartum CBT for Depressed Moms May Help Lower Emotion-Regulation Risks in Infants

Experiments in Rodents Suggest Feasibility of Modifying or Erasing Traumatic Fear Memories

READ

Posted: Thursday, May 13, 2021

Experiments in Rodents Suggest Feasibility of Modifying or Erasing Traumatic Fear Memories

Medicine to Treat Premenstrual Mood Disorder is Tested

READ

Posted: Thursday, May 6, 2021

Medicine to Treat Premenstrual Mood Disorder is Tested

In Early Schizophrenia, Long-Acting Injectable Antipsychotic Treatment Lengthened Time to First Hospitalization

READ

Posted: Thursday, March 25, 2021

In Early Schizophrenia, Long-Acting Injectable Antipsychotic Treatment Lengthened Time to First Hospitalization

View All Foundation Grantees

Sort listing by name, grant type, year, illness, or institution (at time of most recent Grant).

View Our Grantee Listing

Donate Now

DONATE

100% of every dollar donated for research is invested in our research grants. Our operating expenses are covered by separate foundation grants.

The Brain & Behavior Research Foundation is a 501(c)(3) nonprofit organization, our Tax ID # is 31-1020010.

Next-Generation Therapies